2.36
-1.28 (-35.12%)
| Previous Close | 3.63 |
| Open | 3.55 |
| Volume | 2,324,198 |
| Avg. Volume (3M) | 574,703 |
| Market Cap | 150,013,936 |
| Price / Sales | 1.38 |
| Price / Book | 2.32 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2026 |
| Profit Margin | -36.23% |
| Operating Margin (TTM) | -323.11% |
| Diluted EPS (TTM) | -0.880 |
| Quarterly Revenue Growth (YOY) | 44.90% |
| Quarterly Earnings Growth (YOY) | 220.80% |
| Total Debt/Equity (MRQ) | 47.35% |
| Current Ratio (MRQ) | 3.28 |
| Operating Cash Flow (TTM) | -69.62 M |
| Levered Free Cash Flow (TTM) | -40.45 M |
| Return on Assets (TTM) | -26.29% |
| Return on Equity (TTM) | -60.25% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | MacroGenics, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Relative Valuation | 5.0 |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | -0.71 |
Select this tab to load the latest available analysis.
|
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 3.01% |
| % Held by Institutions | 73.84% |
No data within this time range.
No data within this time range.
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |